Global cell expansion market is estimated to be valued at USD 19.69 Bn in 2024 and is expected to exhibit a CAGR of 11.8% during the forecast period (2024-2031).
Development of new technologies in cell expansion is expected to offer lucrative growth opportunities for players in the global cell expansion market, over the forecast period.
Development of new technologies in cell expansion is expected to offer lucrative growth opportunities for players in the global cell expansion market. For instance, in March 2022, WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA), which is a state-of-the-art novel process for scalable manufacture of transfection-free adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. TESSA, is developed by OXGENE in the U.K., a WuXi Advanced Therapies firm, which will speed up AAV manufacture and lower the cost of cell and gene therapies manufacturing, allowing worldwide customers to offer more accessible ground-breaking treatments to patients as rapidly as feasible.
Market- Trends
Cell Expansion Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients